SCHEMBL13675669

SCHEMBL13675669

BCc1ccc(OCOC)cc1Cl

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FYN P06241 4/20 0.35
KDM4E B2RXH2 3/20 0.34
HTT P42858 1/20 0.34
KCNH2 Q12809 4/20 0.34
HTR2A P28223 3/20 0.33
SLC6A4 P31645 3/20 0.33
ALDH1A1 P00352 2/20 0.33
MAOA P21397 1/20 0.32
MAOB P27338 1/20 0.32
MMP2 P08253 1/20 0.32
MMP3 P08254 1/20 0.32
MMP9 P14780 1/20 0.32
MMP14 P50281 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
NR4A2 P43354 1/20 0.32
LMNA P02545 1/20 0.32
MCL1 Q07820 1/20 0.32
FFAR1 O14842 1/20 0.32
IDO1 P14902 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4519124 0.83 KDM4E (0.37) FYNKDM4EHTTKCNH2HTR2A
SCHEMBL12879014 0.82 SLC6A4 (0.46) KDM4EKCNH2HTR2ASLC6A4ALDH1A1
SCHEMBL15114753 0.80 KDM4E (0.50) KDM4EKCNH2HTR2ASLC6A4ALDH1A1
SCHEMBL17658992 0.77 MRGPRX4 (0.40) FYNKDM4ESLC6A4ALDH1A1L3MBTL1
SCHEMBL4500324 0.77 DRD2 (0.49) KDM4EKCNH2HTR2ASLC6A4ALDH1A1
SCHEMBL19816715 0.75 MAPT (0.44) HTTKCNH2HTR2ASLC6A4ALDH1A1
SCHEMBL27172043 0.75 KDM4E (0.36) FYNKDM4EKCNH2SLC6A4ALDH1A1
SCHEMBL30922427 0.75 CYP3A4 (0.42) FYNKDM4EALDH1A1
SCHEMBL1958623 0.75 TSHR (0.42) FYNKDM4EALDH1A1MAOAMAOB
SCHEMBL10218896 0.73 MCL1 (0.57) KDM4EHTTALDH1A1L3MBTL1MCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes HSD11B1, HSD17B1, HSD11B2 FYN 4165/4885KDM4E 2703/4885HTT 3659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.